HypertensionCohort study
Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study
- Population-based cohort study
- healthcare utilization database
Authors' conclusion
In a real-life setting, adherence to antihypertensive drug treatment reduced CV risk in young adults as much as in middle-aged patients.
Study context
- Population
- Residents aged 18–55 years newly prescribed antihypertensive drugs, Lombardy (Italy), 2009–2017
- Participants
- 286,751 residents
- Exposure
- Adherent vs non-adherent to antihypertensive drugs
- Outcome
- Hospital admissions for CV events
- Follow-up
- About 6 years
Main finding
As reported in the abstract
Hospitalization for CV outcome, by age group · about 6 years
Adherent vs Non-adherentHazard ratio (95% CI)
aged 18-39 years
0.78(0.65–0.94)
aged 40-55 years
0.80(0.76–0.84)
Observational data: associations, not effects.
Secondary outcomes
Cardiovascular (CV) and all-cause mortality, by age group
- CV mortality, aged 40-55 (adherent vs non-adherent)
- −18%, 6-28%
- All-cause mortality, aged 40-55 (adherent vs non-adherent)
- −30%, 27-33%
- No significant effects on CV or all-cause mortality, aged 18-39
Original publication
Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. Eur Heart J. Published 25 September 2025. doi:10.1093/eurheartj/ehaf744
Summarised from the published abstract; every number is checked against it